| [1] |
Man M, Cazacu M, Oniu T. Krukenberg tumors of gastric origin versus Krukenberg tumors of colorectal origin[J]. Chirurgia(Bucur), 2007,102(4):407-410.
|
| [2] |
Kim HK, Heo DS, Bang YJ, et al. Prognostic factors of Krukenberg's tumor[J]. Gynecol Oncol, 2001,82(1):105-109. DOI: 10.1006/gyno.2001.6210.
|
| [3] |
Tran PN, Sarkissian S, Chao J, et al. PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence[J]. Gastrointest Cancer, 2017,7:1-11. DOI: 10.2147/GICTT.S113525.
|
| [4] |
Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial[J]. JAMA Oncol, 2020,6(10):1571-1580. DOI: 10.1001/jamaoncol.2020.3370.
|
| [5] |
Shitara K, Özgüro$\check{g}$lu M, Bang YJ, et al. Pembolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial [J]. Lancet, 2018,392(10142):123-133. DOI: 10.1016/S0140-6736(18)31257-1.
|
| [6] |
Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017,390(10111):2461-2471. DOI: 10.1016/S0140-6736(17)31827-5.
|
| [7] |
Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial[J]. JAMA Oncol, 2018, 4(5): e180013. DOI 10.1001/jamaoncol.2018.0013.
|
| [8] |
Xu J, Zhang Y, Jia R, et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study[J]. Clin Cancer Res, 2019,25(2):515-523. DOI: 10.1158/1078-0432.CCR-18-2484.
|
| [9] |
Huang J, Mo H, Zhang W, et al. Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China[J]. Cancer, 2019,125(5):742-749. DOI: 10.1002/cncr.31855.
|
